不同脱细胞真皮基质在乳房再造中的比较:一项自身对照研究
本研究为前瞻性、患者盲法自身对照研究,纳入2019至2022年间行双侧乳头和/或保留皮肤乳房切除术并置入组织扩张器或硅胶假体的患者,将两种脱细胞真皮基质产品随机分配至左右乳房。结果显示AlloDerm组血清肿发生率高于DermACELL组(30.91% vs 14.55%,P<.05),整合率低于DermACELL组(93.4% vs 99.8%,P<.05),两组再造成功率均为94.55%。
要点
- AlloDerm组血清肿发生率30.91%,高于DermACELL组的14.55%(P<.05)。
- AlloDerm整合率93.4%,低于DermACELL的99.8%(P<.05)。
- 两种产品再造成功率均为94.55%,引流管拔除时间无显著差异。
核心结论
- 无论患者人口学差异如何,两种产品的再造成功率均为94.55%。
- AlloDerm术后血清肿发生率更高,且整合率有更低趋势。
研究设计与样本
- 前瞻性、患者盲法自身对照研究,2019至2022年间纳入55例患者(110侧乳房),行双侧乳头和/或保留皮肤乳房切除术并置入组织扩张器或硅胶假体。
- 两种产品随机分配至左或右乳房,以患者自身为对照,随访记录90天。
主要发现
- 引流管拔除时间、平均引流量及血清肿抽吸量在两种产品间无显著差异。
- AlloDerm组血清肿发生率30.91%,高于DermACELL组的14.55%(P<.05)。
- AlloDerm整合率93.4%,低于DermACELL的99.8%(P<.05)。
关键数值与推荐
- AlloDerm组血清肿发生率30.91% vs DermACELL组14.55%(P<.05)。
- AlloDerm整合率93.4% vs DermACELL 99.8%(P<.05)。
- 两种产品再造成功率均为94.55%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since the early 2000s, acellular dermal matrix has been a popular adjunct to prepectoral breast reconstruction to enhance outcomes. OBJECTIVES: The aim of this study was to investigate the differences in the postoperative course of 2 standard acellular dermal matrix products, AlloDerm SELECT Ready To Use and DermACELL. METHODS: A prospective, patient-blind study of patients undergoing bilateral nipple and/or skin-sparing mastectomies with either tissue expander or silicone implant insertion between 2019 and 2022 were selected for this study. The study design used patients as their own controls between 2 products randomly assigned to the left or right breast. Outcomes between the products included average time for drain removal, infection rate, seroma rate, and incorporation rates. RESULTS: The prospective clinical data of 55 patients (110 breasts) were recorded for 90 days. There were no significant differences between drain removal time, average drain output, or seroma aspiration amount. A higher percentage of seromas was recorded in the breasts with AlloDerm (30.91%) compared with breasts containing DermACELL (14.55%, P < .05), and a statistically significant difference between the incorporation rates of AlloDerm (93.4%) and DermACELL (99.8%, P < .05) was observed. CONCLUSIONS: Irrespective of patient demographic disparities, both products had a 94.55% success rate for reconstruction outcomes. AlloDerm was determined to have a higher incidence of seromas as a postoperative complication and a trend to lower incorporation.
引用
- Davison SP, Harbour S, Fassihi E, et al. Comparison of Different Acellular Dermal Matrix in Breast Reconstruction: A Skin-to-Skin Study. Aesthet Surg J. 2024. PMID: 38377366. doi:10.1093/asj/sjae035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。